Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for...
Reexamination Certificate
2005-12-27
2005-12-27
Meller, Michael (Department: 1654)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Reexamination Certificate
active
06979563
ABSTRACT:
A highly purified and specific glycosaminoglycan degrading enzyme, chondroitinase AC, and to a lesser extent, chondroitinase B, can be used in the treatment of metastatic cancers and in other disorders characterized by angiogenesis. The enzymatic removal of chondroitin sulfates A and C, and to a lesser extent, chondroitin sulfate B, from cell surfaces directly decreases the ability of tumor cells to invade blood vessels and thus prevents the formation of metastatic, or secondary tumors; inhibits tumor cell growth; and decreases angiogenesis by inhibiting both endothelial cell proliferation and capillary formation. Decreasing the formation of new blood vessels into the tumor in turn decreases the potential for tumor growth, and further decreases the ability of tumor cells to invade the bloodstream. These effects are opposite to the prometastatic effects of tumor-secreted heparanase.
REFERENCES:
patent: 4696816 (1987-09-01), Brown
patent: 5567417 (1996-10-01), Sasisekharan et al.
patent: 5945403 (1999-08-01), Folkman et al.
patent: 51075042 (1979-06-01), None
patent: WO 96/01648 (1996-01-01), None
patent: WO 96/01894 (1996-01-01), None
patent: WO 96/08559 (1996-03-01), None
Takeuchi, Brit. J. Cancer, 1972, 26(2), 115-119.
Crum, et al., “A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment,”Science230(4732): 1375-1378 (1985).
Culp, et al., “Two functionally distinct pools of glycosaminoglycan in the substrate adhesion site of murine cells,”J. Cell Biol.79(3):788-801 (1978).
Denholm, et al., “The effects of bleomycin on alveolar macrophage growth factor secretion,”Am J Pathol.134(2):355-63 (1989).
Denholm, et al., “Chondroitinase AC inhibits tumor cells invasion, proliferation, and angiogenesis,”FASEB J14(4): A702 (2000).
Denholm, et al., “Anti-tumor activities of chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation and invasion,”Eur J Pharmacol416(3): 213-221 (20001).
Faassen, et al., “A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion,”J. Cell Biol.116(2):521-531 (1992).
Faassen, et al., “Cell surface CD44-related chondroitin sulfate proteoglycan in required for transforming growth factor-beta-stimulated mouse melanoma cell motility and invasive behavior on type I collagen,”J. Cell Science105(Pt 2):501-511 (1993).
Folkman, “Angiogenesis in cancer, vascular, rheumatoid and other disease,”Nat Med1(1):27-31 (1995).
Folkman, “Successful treatment of an angiogenic disease,”N. Engl. J. Med.320(18): 1211-1212 (1989).
Folkman, “Tumor angiogenesis: therapeutic implications,” N. Engl. J. Med. 285(21): 1182-1186 (1971).
Folkman, et al., “Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone,”Science221(4612): 719-725 (1983).
Folkman, et al., “Control of angiogenesis with synthetic heparin substitutes,”Science243(4897): 1490-1493 (1989).
Forrester, et al., “A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies,”J. Am. Coll. Cardiol.17(3):758-769 (1991).
Gu, et. al., “Purification, characterization and specificity of chondroitin lyases and glycuronidase fromFalvobacterium heparinum,” Biochem. J.312(Pt 2):569-577 (1995).
Henke, et. al., “CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix,”J. Clin. Invest.97(11):2541-2552 (1996).
Ingber, et al., “Inhibition of angiogenesis through modulation of collagen metabolism,”J. Lab. Invest.59: 44-51 (1989).
Ingber, et al., “A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution,”Endocrinol.119(4): 1768-1775 (1986).
Ingber, et al., “Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix,” J. Cell. Biol. 109(1): 317-330 (1989).
Jackson et. al., “Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes,”Physiol. Rev.71(2):481-530 (1991).
Jin-Inchi, et al., “Inhibition of experimental metastasis of murine Lewis lung carinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action,”Cancer Res.50:6731-6737 (1990).
Lida, et al., “Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion,”Sem. Cancer Biol.7:155-162, (1996).
Linhardt, et al., “Polysaccharide lyases,”Appl. Biochem. Biotech.12(2): 135-176 (1986).
Linn et. al., “Isolation and characterization of two chondroitin lyases from Bacteroides thetaiotaomicron,” J.Bacteriol.156(2):859-866 (1983).
Meyer, et al., “Mechanisms of tumour metastasis,”Eur. J. Cancer34(2):214-221 (1998).
Michelacci, et al., “Isolation and characterization of an induced chondroitinase ABC fromFlavobacterium heparinum,” Biochim. Biophys. Acta.923(2):291-301 (1987).
Murray, et al., “Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor,”J. Biol. Chem.261(9): 4154-4159 (1986).
Nakajima, et al., “Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines,”Science220(4597):611-613 (1983).
Richardson, et al., “Transient morphological and biochemical alterations of arterial proteoglycan during early wound healing,”Exp. Mol. Pathol.58(2):77-95 (1993).
Sato, et al., “Submit structure of Chondroitinase ABC fromProteus vulgaris,” Agric. Biol. Chem.50:1057-1059 (1986).
Tabas, et al., “Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation,”J. Biol. Chem.268(27):20419-20432 (1993).
Takeuchi, “Effect of chondroitinases on the growth of solid Ehrlich ascites tumour,”Brit J Cancer26(2): 115-119 (1972).
Trochan, et al., “Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro,”Int. J. Cancer66:664-668 (1996).
Volpi, “Fast moving and slow moving heparins, dermatan sulfate, and chondroitin sulfate: qualitative and quantitative analysis by agarose-gel electrophoresis,”Carbohydrate Res.247:263-278 (1993).
Yeo, et al., “Alterations in proteoglycan synthesis common to healing wounds and tumors,” Am. J. Pathol. 138(6):1437-1450 (1991).
Zawadzki, et al., “Blackade of metastasis formation by CD44-receptor globulin,”Int. J. Cancer75(6):919-924 (1998).
Denholm Elizabeth M.
Lin Yong-Qing
Silver Paul J.
BioMarin Enzymes, Inc.
Meller Michael
Pabst Patent Group LLP
LandOfFree
Attenuation of tumor growth, metastasis and angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuation of tumor growth, metastasis and angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuation of tumor growth, metastasis and angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3469733